May 2022

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Press releases

LUMICKS Appoints Andre Nel as Chief Financial Officer

We are very pleased to attract an experienced life sciences financial executive like Andre to LUMICKS at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide.

j.yeh9 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Join our newsletter